Vertex Pharma stock: Citi keeps USD 585.00 target for Vertex Pharma stock

Published on 10/16/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 3.33 billion versus USD 2.96 billion a year earlier. Vertex Pharma stock costs EUR 450.88 on October 16, 2026.

Citi target and quarterly revenue

Citi analyst Geoff Meacham maintained a USD 585.00 target for Vertex Pharma on October 13, 2026.
Vertex reported USD 3.33 billion in second-quarter 2026 revenue against USD 2.96 billion a year earlier.
Vertex Pharma stock costs EUR 450.88 at Lang & Schwarz on October 16, 2026 at 5:12 p.m. CEST.
Vertex plans to report third-quarter 2026 results on November 2, 2026.

Pop-Art-Comic-Illustration eines Wissenschaftlers, der ein leuchtendes Reagenzglas hochhält — Vertex Pharma US92532F1003 zeigt eine farbenfrohe Pop-Art-Comic-Szene eines Wissenschaftlers mit leuchtendem Reagenzglas, Illustration mit AI erstellt.

Citi analyst Geoff Meacham maintained a Buy rating and set a USD 585.00 price target for Vertex Pharmaceuticals on October 13, 2026, according to The Globe and Mail. Against the Nasdaq quotation of USD 505.13 on October 16, 2026 at 11:24 a.m. ET, that target stands 15.81 percent higher. Vertex Pharma stock was trading at EUR 450.88 at Lang & Schwarz on October 16, 2026 at 5:12 p.m. CEST.

Quarterly revenue sets the baseline

Vertex reported USD 3.33 billion in revenue for the second quarter of 2026, compared with USD 2.96 billion in the second quarter of 2025, according to The Globe and Mail. Net profit rose from USD 1.03 billion to USD 1.10 billion over the same year-over-year comparison. The figures give the analyst target a current operating backdrop rather than a purely technical valuation reference.

Stock remains below its yearly high

The Nasdaq quotation was USD 505.13 on October 16, 2026 at 11:24 a.m. ET, with a day range of USD 504.68 to USD 511.44. Vertex Pharmaceuticals traded between USD 403.16 and USD 560.25 over the 52 weeks through that date. The latest Nasdaq price therefore stood 9.84 percent below the 52-week high. Trading volume was 436,951 shares, compared with an average volume of 1,175,751 shares.

Valuation and the next date

Vertex Pharmaceuticals had a market capitalization of USD 128.0 billion and a price-to-earnings ratio of 29.53 as of October 16, 2026. The company is scheduled to report third-quarter 2026 financial results on November 2, 2026, after the market close, according to Vertex Pharmaceuticals. The company said its earnings call will begin at 4:30 p.m. ET that day.

What the target means for valuation

Citi's USD 585.00 target is 15.81 percent above the Nasdaq price cited on October 16, 2026. That comparison places the analyst view above the current quotation while the stock remains below its USD 560.25 52-week high. The upcoming November 2 report is the next scheduled company event that could update revenue, earnings and forward expectations.

Vertex Pharma stock price at Lang & Schwarz

Vertex Pharma stock was trading at EUR 450.88 at Lang & Schwarz on October 16, 2026 at 5:12 p.m. CEST. On the Nasdaq, the stock was last at USD 505.13 on October 16, 2026 at 11:24 a.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.